

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) ~~Use of~~A method of treating cancer by chemo-brachytherapy comprising administering to a subject by intra-tumoral administration a pharmaceutical composition comprising a cytotoxic drug and a porous carrier material ~~in the preparation of a medicament for the intra-tumoural delivery of a cytotoxic drug in a method of treating a cancer by chemo-brachytherapy.~~
2. (currently amended) ~~[[Use]]~~The method according to claim 1 wherein the porous carrier material is doped or undoped silicon, germanium, silicon carbide or silicon nitride.
3. (currently amended) ~~[[Use]]~~The method according to claim 1 wherein the porous carrier material is silicon.
4. (currently amended) ~~[[Use]]~~The method according to claim 3 wherein the silicon is resorbable.
5. (currently amended) ~~[[Use]]~~The method according to claim 4 where the resorbable silicon is mesoporous.
6. (currently amended) ~~[[Use]]~~The method according to claim 1 wherein [[a]]~~the~~ cytotoxic drug is incorporated into the pores of the porous carrier material.

7. (currently amended) [[Use]]The method according to claim 1 wherein the cytotoxic drug is present in an amount of from 15% to 85% by weight, based on the weight of the composition.

8. (currently amended) [[Use]]The method according to claim 1 wherein the cytotoxic drug is selected from chlorambucil and paclitaxel.

9. (currently amended) [[Use]]The method according to claim 1 wherein the pharmaceutical composition comprises a multiplicity of microparticles.

10.-12. (canceled).

13. (currently amended) Use of aThe method of claim 1 in which the porous carrier material having~~as~~ a cytotoxic drug incorporated into the pores thereof to ~~delivery~~deliver a cytotoxic drug at a dose higher than the LD50 of the corresponding free drug ~~in a method of treating a cancer.~~

14. (currently amended) [[Use]]The method according to claim 13 wherein the cytotoxic drug is selected from chlorambucil and paclitaxel.

15.-17. (canceled).

18. (original) A method for treating a cancer by chemo-brachytherapy comprising introducing to the site at which the cancer is located a pharmaceutical composition comprising a porous carrier material and a cytotoxic agent selected from chlorambucil and paclitaxel.

19. (previously presented) A method according to claim 18 wherein the porous carrier material is silicon.

20. (previously presented) A method according to claim 18 wherein the pharmaceutical composition is introduced to the site at which the cancer is located by injecting a suspension of microparticles into an artery or vein connected to or located in the organ in which the cancer tumour is located.

21. (previously presented) A method according to claim 18 wherein the pharmaceutical composition is introduced to the site at which the cancer is located by injecting a suspension of microparticles into the cancer tumour.